Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 10Gemcitabine 8Cisplatin 7Hepatectomy 6Fluorouracil 6Radiofrequency Ablation 5Liver Transplantation 5Irinotecan 5Capecitabine 5lenvatinib 4Paclitaxel 4Neoadjuvant Therapy 4Folfox protocol 4Cetuximab 4Aspirin 4tislelizumab 3Surgical Procedures, Operative 3Nivolumab 3Carboplatin 3titanium silicide 2durvalumab 2apatinib 2Trastuzumab 2S 1 (combination) 2Leucovorin 2Lamivudine 2Introns 2Ethiodized Oil 2Drug Therapy 2DNA, Mitochondrial 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × CLR1404 × Gastrointestinal × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡